JP2017500289A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500289A5
JP2017500289A5 JP2016531049A JP2016531049A JP2017500289A5 JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5 JP 2016531049 A JP2016531049 A JP 2016531049A JP 2016531049 A JP2016531049 A JP 2016531049A JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5
Authority
JP
Japan
Prior art keywords
ethoxy
amino
acetyl
hpyy
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500289A (ja
JP6629198B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/074477 external-priority patent/WO2015071356A1/en
Publication of JP2017500289A publication Critical patent/JP2017500289A/ja
Publication of JP2017500289A5 publication Critical patent/JP2017500289A5/ja
Application granted granted Critical
Publication of JP6629198B2 publication Critical patent/JP6629198B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016531049A 2013-11-15 2014-11-13 35位にβ−ホモアルギニン置換を有するHPYY(1−36) Active JP6629198B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13193080.2 2013-11-15
EP13193080 2013-11-15
US201361906022P 2013-11-19 2013-11-19
US61/906,022 2013-11-19
PCT/EP2014/074477 WO2015071356A1 (en) 2013-11-15 2014-11-13 Hpyy(1 -36) having a beta-homoarginine substitution at position 35

Publications (3)

Publication Number Publication Date
JP2017500289A JP2017500289A (ja) 2017-01-05
JP2017500289A5 true JP2017500289A5 (https=) 2017-12-07
JP6629198B2 JP6629198B2 (ja) 2020-01-15

Family

ID=49582656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531049A Active JP6629198B2 (ja) 2013-11-15 2014-11-13 35位にβ−ホモアルギニン置換を有するHPYY(1−36)

Country Status (5)

Country Link
US (1) US10583172B2 (https=)
EP (1) EP3068795B1 (https=)
JP (1) JP6629198B2 (https=)
CN (1) CN105764919B (https=)
WO (1) WO2015071356A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー/エス Glp−1化合物の経口投薬
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MA43205A (fr) * 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
US20220280611A1 (en) * 2019-08-07 2022-09-08 Novo Nordisk A/S Solid composition comprising a pyy compound and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
EP4058047A1 (en) * 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK121895A3 (en) 1993-03-29 1996-10-02 Univ Cincinnati Analogues of peptide yy and uses thereof
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
CA2271788A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ アルブミン様物質に結合した新規のglp−1類似物
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
AU2005224027B2 (en) 2004-03-17 2011-05-26 7Tm Pharma A/S Y2/Y4 selective receptor agonists for therapeutic interventions
CN1933848A (zh) 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
CA2560174A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2009500453A (ja) 2005-07-11 2009-01-08 ナステック ファーマスーティカル カンパニー インク. 向上されたpyyの粘膜送達用製剤
AU2006271792A1 (en) 2005-07-18 2007-01-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
AU2005337116A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
ATE516301T1 (de) 2005-09-21 2011-07-15 7Tm Pharma As Y2-selektive rezeptoragonisten für therapeutische eingriffe
RU2430108C2 (ru) 2005-12-07 2011-09-27 Ф.Хоффманн-Ля Рош Аг Агонисты рецептора нейропептида-2
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
EP2106405A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Peptides for use in the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CN101970475A (zh) 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100204113A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
CN102027007A (zh) * 2008-05-16 2011-04-20 诺沃-诺迪斯克有限公司 长效的y2和/或y4受体激动剂
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
WO2010052144A2 (en) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
CN102325545A (zh) 2009-02-20 2012-01-18 益普生制药股份有限公司 具有神经肽y受体结合化合物的细胞毒性缀合物
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
IN2012DN03042A (https=) 2009-10-13 2015-07-31 Hoffmann La Roche
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations

Similar Documents

Publication Publication Date Title
JP2017500289A5 (https=)
JP2017505284A5 (https=)
RU2017145348A (ru) Селективные соединения пептида yy и их применения
JP2018522843A5 (https=)
JP2013525444A5 (https=)
JP2013533227A5 (https=)
JP2015517459A5 (https=)
JP2016510326A5 (https=)
JP2013519675A5 (https=)
JP2016006096A5 (https=)
JP2015513544A5 (https=)
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
EP4410833A3 (en) Compositions and methods for treating fatty tissue buildup
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
JP2013522326A5 (https=)
NZ600477A (en) Insulin analogues with chlorinated amino acids
JP2011046708A5 (https=)
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2017014206A5 (https=)
JP2017522300A5 (https=)
JP2015514781A5 (https=)
WO2014071405A3 (en) Long-acting single-chain insulin analogues
JP2015516419A5 (https=)
HK1251998A1 (zh) 佐米曲普坦肺部给药粉
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population